Abstract

Boston Scientific will release first‑quarter 2026 results on April 22, 2026 Pre-Market, and investors are watching revenue growth, margins, and EPS against a backdrop of mixed electrophysiology sentiment and strong analyst support.

Market Forecast

Consensus and the company’s latest quarterly outlook point to first‑quarter revenue of 5.17 billion US dollars, implying 13.09% year‑over‑year growth, with adjusted EPS around 0.79, implying 17.18% year‑over‑year growth; EBIT is projected near 1.43 billion US dollars with a 16.59% year‑over‑year increase. Forecast disclosure for gross margin and net margin by quarter is not available, but the revenue and EPS trajectory indicates the market expects solid double‑digit growth to continue into the March quarter.

Boston Scientific’s revenue mix remains centered on its core franchises, with approximately 66.01% of revenue coming from cardiovascular procedures and the remaining 33.99% from medical and surgical therapies, based on the company’s latest mix. The most promising near‑term growth engine remains electrophysiology, which delivered 0.89 billion US dollars in the fourth quarter with 35% organic growth, setting up a debated, high‑visibility swing factor for the coming print.

Last Quarter Review

In the prior quarter, Boston Scientific reported revenue of 5.29 billion US dollars, a gross profit margin of 69.47%, GAAP net income attributable to shareholders of 672.00 million US dollars with a net profit margin of 12.71%, and adjusted EPS of 0.80, up 14.29% year over year; total revenue rose 15.90% year over year and modestly exceeded estimates.

A key financial highlight was a clean top‑ and bottom‑line beat versus consensus, with revenue and EPS both finishing slightly above expectations, demonstrating continued operating leverage despite mixed product‑level performance. Within the portfolio, electrophysiology generated 0.89 billion US dollars in the quarter with 35% organic growth, while left‑atrial appendage closure (LAAC, Watchman) tracked about 1% below consensus, underscoring why these franchises are central to investor debates into the current quarter.

Current Quarter Outlook (with major analytical insights)

Main businesses: what to watch across core franchises

The company’s core franchises set the baseline for this quarter’s performance, with cardiovascular therapies representing roughly two‑thirds of revenue and medical and surgical contributing the balance. Management’s steady execution last quarter—evidenced by a 69.47% gross margin and 12.71% net margin—creates a backdrop for incremental operating leverage if mix remains favorable. For the March quarter, the revenue estimate of 5.17 billion US dollars and EPS near 0.79 embeds expectations for healthy procedure activity, relatively stable pricing, and disciplined spending to sustain double‑digit top‑line growth while protecting profitability.

Gross margin is the swing variable underneath EPS, and the path to upside likely runs through product mix and manufacturing efficiencies. If the quarter sees a higher mix of premium devices and continued manufacturing scale benefits, the company can support the projected EBIT of about 1.43 billion US dollars while cushioning any incremental spending tied to launches or clinical programs. Conversely, if the mix skews toward lower‑margin categories or if there is transitory cost pressure associated with expansions and product ramps, EBIT could land closer to expectations rather than exceeding them. The balance between growth investments and cost discipline will be a key read‑through from the management commentary on April 22, 2026.

Procedure cadence and seasonality are relevant considerations into Q1. Analysts have flagged that quarterly phasing can be “choppy,” especially for procedure‑driven categories, which makes intra‑quarter momentum critical. Given that revenue and EPS forecasts imply continued double‑digit expansion, investors will be looking for color on order trends, backlog conversion, and hospital purchasing behavior in the early months of the year. Confirmation that momentum in core businesses is intact should support the current outlook, while any indication of front‑half lumpiness could shift attention to the second quarter and the full‑year trajectory.

Most promising segment: electrophysiology and LAAC momentum into and beyond Q1

Electrophysiology remains the most scrutinized and potentially rewarding growth engine after delivering 0.89 billion US dollars with 35% organic growth in the fourth quarter. The magnitude of this performance has heightened expectations, and it is a focal point for Q1 given the combination of ongoing product rollouts and evolving physician practice patterns. Analyst commentary suggests that while growth drivers are intact, quarterly cadence can vary, making updates on utilization, account activations, and inventory normalization pivotal signals for how this business contributes to the quarter’s EPS.

LAAC is closely tied to the first‑quarter narrative via the CHAMPION‑AF clinical program and its implications for therapy adoption. Recent disclosures indicate the Watchman FLX device met all its primary and secondary safety and efficacy endpoints in a trial evaluating first‑line use versus non‑vitamin K oral anticoagulants, with “statistically superior” protection from bleeding and comparable efficacy to blood thinners. That result supports the longer‑term expansion of eligible patients and provides a favorable clinical backdrop; however, investors will be attentive to how rapidly such evidence translates into procedure growth, referral patterns, and hospital protocols. In the near term, revenue inflection will likely depend on sales execution, site expansion, and physician training scaling rather than immediate guideline shifts.

The interplay between electrophysiology and LAAC creates both opportunity and risk for Q1. Upside comes from continued adoption of newer technologies and strong physician engagement, which can sustain double‑digit revenue growth above the 13.09% market forecast baseline. On the flip side, if procedure volumes reflect early‑year variability or if channel inventory and purchasing cycles normalize after a strong Q4, revenue in these categories could land closer to the midpoint of expectations. The company’s commentary on order book, account conversions, and conversion cycles will be closely parsed to assess how much of the 2026 growth curve is front‑loaded versus distributed through the year.

Key stock‑price drivers this quarter: margin, cadence, and guidance credibility

Three factors are likely to drive the stock’s reaction on April 22, 2026. The first is gross margin trajectory relative to last quarter’s 69.47%: any lift from premium mix and cost efficiencies can translate into operating leverage and an EPS surprise, while a flat or slightly lower margin would keep EPS near the 0.79 projection. The second is top‑line cadence in the procedure‑driven categories; analysts are expecting uneven monthly pacing in early 2026, so an in‑line quarter with stronger order commentary for Q2 could still support shares if management reinforces confidence in the year’s shape. The third is guidance credibility and qualitative color around 2026 growth drivers; confirming momentum in electrophysiology and LAAC against a favorable clinical backdrop would help offset caution stemming from the February volatility following product‑level debates.

Clinical data and launch updates will serve as catalysts beyond the print. Positive read‑throughs from CHAMPION‑AF are already helping de‑risk the LAAC narrative, and clarity on how these results will be communicated to physicians and integrated into care pathways will be important. On the inorganic side, analysts continue to discuss potential portfolio expansion and integration of pipeline assets; any commentary on expected timing, margin impact, and revenue contribution will shape how investors underwrite the outer‑year earnings power. Lastly, discipline in operating expenses remains a watchpoint: if spending growth tracks below revenue growth while the company continues investing behind high‑return programs, it strengthens the case for sustained EPS compounding.

Analyst Opinions

Bullish views dominate recent commentary between January 1, 2026 and April 15, 2026. Across the period, the balance of opinions skews heavily positive—roughly nine bullish notes to one cautious take—driven by expectations for sustained double‑digit revenue growth in the March quarter and an improving clinical and commercial setup for LAAC and electrophysiology.

Institutions emphasizing a positive stance include Oppenheimer, which highlighted the importance of the CHAMPION‑AF readout and maintained an Outperform rating with a 100 US dollars price target, calling the trial one of the year’s key clinical events and noting that its success should help expand the addressable base over time. RBC underscored an Outperform view while acknowledging that quarterly cadence “can be choppy” and that investor focus remains elevated on first‑quarter execution; RBC framed 2026 guidance as reasonable and reiterated that sentiment is chiefly tied to the Q1 performance of pulse‑field ablation and LAAC. Jefferies maintained a Buy and adjusted its price target in late March, reinforcing confidence that the growth algorithm remains intact while valuation reflects near‑term execution risk. BTIG kept a Buy with a 110 US dollars price target in mid‑April, arguing that the risk‑reward has improved following share volatility and that the setup into the print looks constructive. Goldman Sachs and Stifel each maintained Buy ratings while adjusting targets modestly in late March and early April, citing robust fundamental drivers and the supportive clinical backdrop. Evercore ISI sustained an Outperform, pointing to multiple growth vectors across the portfolio as well as improving visibility in key programs. TD Cowen reiterated Buy in February and again in March, highlighting momentum in core cardiac therapies and reinforcing the view that LAAC adoption could accelerate as data dissemination progresses.

The one prominently cautious perspective during the period stemmed from February’s reaction to product‑level revenue debates, with investors focusing on a softer comparison against Street expectations in specific franchises during the fourth quarter. However, the majority view has not shifted: analysts broadly expect the March quarter to show solid double‑digit year‑over‑year revenue growth near the 13.09% forecast, with an EPS outcome around 0.79 and upside potential dependent on gross‑margin mix and the pacing of electrophysiology and LAAC procedures. The consensus message is that strong clinical validation for the Watchman FLX device, discipline on spending, and execution across the cardiovascular and medical‑surgical foundations position the company favorably for 2026, even if quarter‑to‑quarter variability persists in procedure‑driven lines.

Putting these opinions together, the prevailing theme into April 22, 2026 is constructive. Most institutions expect Boston Scientific to deliver revenue growth in line with or slightly above the 5.17 billion US dollars projection, maintain healthy profitability, and use CHAMPION‑AF momentum to reinforce the multi‑quarter LAAC narrative. The stock’s near‑term path is expected to be driven by whether management’s commentary bridges consensus to a clear cadence for Q2 and beyond, how gross margin trends relative to the 69.47% baseline, and whether the company’s core franchises continue to convert pipeline opportunities into procedure growth. On balance, the majority bullish camp sees more support than resistance on these counts, which is why Buy and Outperform ratings remained prevalent through April 15, 2026.